Trelegy Ellipta (Fluticasone furoate + umeclidinium bromide + vilanterol trifenatate Inhaler) 92mcg+55mcg+22mcg

Trelegy Ellipta inhaler combines fluticasone furoate, umeclidinium bromide, and vilanterol trifenatate for long-term COPD and asthma maintenance. This triple therapy inhaler delivers 30 doses in a single device for convenient daily use. Trelegy Ellipta helps manage breathing symptoms effectively with once-daily dosing.

Strength

92mcg+55mcg+22mcg

Pack Size

1x30doses

Storage

Ambient

Manufacturer / TM Owner

GlaxoSmithKline Phamraceuticals Ltd

Select Quantity

Pack/s

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

First Name

Last Name

Phone

Delivery Country

Delivery PostCode/Zipcode

Select Your Profile

I have read and agree to the terms & conditions, including the privacy policy, return policy, and usage terms as applicable to this request.

Indications & Clinical Uses

Trelegy Ellipta inhaler is used for long-term maintenance treatment of chronic obstructive pulmonary disease (COPD) and asthma in adults. It combines an inhaled corticosteroid (fluticasone), a long-acting muscarinic antagonist (umeclidinium), and a long-acting beta2-adrenergic agonist (vilanterol) to improve breathing and reduce flare-ups. This inhaler is designed for daily use to control symptoms and prevent exacerbations in patients who require multiple therapies.

Side Effects

Users of Trelegy Ellipta inhaler may experience improved breathing and reduced wheezing or shortness of breath over time. Some may notice fewer asthma attacks or COPD flare-ups when using the inhaler as prescribed. The device delivers medication directly to the lungs for targeted relief with minimal systemic effects.

Precautions & Warnings

Keep the Trelegy Ellipta inhaler away from moisture and store at room temperature. Always check the dose counter before use and discard the inhaler after 30 doses or when the counter reads zero. Rinse your mouth with water after each use to reduce the risk of oral infections. Consult your healthcare provider if symptoms worsen or do not improve.

Avoid Interactions

Avoid using Trelegy Ellipta inhaler with other long-acting beta-agonists or anticholinergics unless directed by a healthcare provider. Certain medications, such as strong CYP3A4 inhibitors, may increase the risk of side effects. Inform your doctor about all medications, including over-the-counter drugs and supplements, before starting this inhaler.

Frequently Asked Questions

It is used for long-term maintenance treatment of COPD and asthma in adults who require multiple therapies.

Each inhaler contains 30 doses, as indicated by the dose counter.

Yes, it is designed for once-daily use as prescribed by a healthcare provider.

Take the missed dose as soon as you remember, but skip it if it is almost time for the next dose.

Common effects may include sore throat, headache, or cough; consult your doctor if symptoms persist.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated: 29 Jul 2026

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.